Top Banner
BRONCHITIS GRUP 6 Farmakoterapi II kelas A 1. Melisa Amir 2. Nur Asma 3. Nur Irjawati S.K 4. Muti Purnama S. 5. Ananda Lisda P. FAKULTAS FARMASI UNIVERSITAS HASANUDDIN
40
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Klp 6_farmakoterapi II Bronkitis & Pneumonia

BRONCHITISGRUP 6 Farmakoterapi II kelas A

1. Melisa Amir2. Nur Asma3. Nur Irjawati S.K4. Muti Purnama S.5. Ananda Lisda P.

FAKULTAS FARMASIUNIVERSITAS HASANUDDIN

Page 2: Klp 6_farmakoterapi II Bronkitis & Pneumonia

DEFINITION

Pharmacotherapy handbook page : 465

Page 3: Klp 6_farmakoterapi II Bronkitis & Pneumonia

CLASSIFICATION

Bronchitis

Acute bronchitis

Chronic Bronchitis

Page 4: Klp 6_farmakoterapi II Bronkitis & Pneumonia

ACUTE BRONCHITIS

Acute bronchitis most commonly occurs during the winter months. Cold, damp climates and/or the presence of high concentrations of irritating substances such as air pollution or cigarette smoke may precipitate attacks.

Pharmacotherapy handbook page : 465

Page 5: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Pathophysiology

Pharmacotherapy handbook page : 465

Page 6: Klp 6_farmakoterapi II Bronkitis & Pneumonia
Page 7: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Page 8: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Desired Outcome

The goals of therapy are to provide comfort to the patient and, in the unusually severe case, to treat associated dehydration and respiratory compromise

Page 9: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment

Page 10: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment

Page 11: Klp 6_farmakoterapi II Bronkitis & Pneumonia

CHRONIC BRONCHITIS

Chronic bronchitis is defined clinically as a chronic productive cough for at least 3 months in each of two consecutive years in a patient in whom other causes have been excluded

Pharmacotherapy principles & practice page : 272

Page 12: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Pathophysiology

Page 13: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Pictures

Page 14: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Page 15: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Page 16: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Page 17: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Page 18: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Page 19: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Desired Outcome

The goals of therapy for chronic bronchitis are to reduce the severity of symptoms, to ameliorate acute exacerbations, and to achieve prolonged infection-free intervals.

Page 20: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment

Page 21: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment

Page 22: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment

Page 23: Klp 6_farmakoterapi II Bronkitis & Pneumonia
Page 24: Klp 6_farmakoterapi II Bronkitis & Pneumonia

PNEUMONIA

Page 25: Klp 6_farmakoterapi II Bronkitis & Pneumonia

DEFINITION

Pharmacotherapy handbook page : 471

Pneumonia is the most common infectious cause of death in the United States. It occurs in persons of all ages, although the clinical manifestations are most severe in the very young, the elderly, and the chronically ill.

Page 26: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Pathophysiology

Pharmacotherapy handbook page : 465

Page 27: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Pathophysiology

Page 28: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical Presentation

Gram-Positive and Gram-Negative Bacterial Pneumonia

Anaerobic Pneumonia

Mycoplasma pneumoniae

Viral Pneumonia

Nosocomial Pneumonia

Page 29: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical PresentationGram-Positive and Gram Negative Bacterial

Pneumonia

BACK

Page 30: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical PresentationAnaerobic Pneumonia

BACK

Page 31: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical PresentationMycoplasma Pneumonia

BACK

Page 32: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical PresentationMycoplasma Pneumonia

BACK

Page 33: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Clinical PresentationViral and Nosocomial Pneumonia

BACK

Page 34: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Desired Outcome

Eradication of the offending organism and complete clinical cure are the primary objectives. Associated morbidity should be minimized (e.g, renal pulmonary, or hepatic dysfunction))

Page 35: Klp 6_farmakoterapi II Bronkitis & Pneumonia

TreatmentTHERAPY FOR ADULTS

Page 36: Klp 6_farmakoterapi II Bronkitis & Pneumonia

TreatmentTHERAPY FOR PEDIATRIC

Page 37: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment with Antibiotic for Bacterial Pneumonia

Page 38: Klp 6_farmakoterapi II Bronkitis & Pneumonia

Treatment

Page 39: Klp 6_farmakoterapi II Bronkitis & Pneumonia

EVALUATION OF THERAPEUTIC OUTCOMES

Page 40: Klp 6_farmakoterapi II Bronkitis & Pneumonia

THANK YOU

WASSALAMUALAIKUM WARAHMATULLAHI WABARAKATUH